SMMT Summit Therapeutics Inc

Summit Therapeutics plc (AIM:SUMM) (NASDAQ:SMMT), the drug discovery and development company advancing therapies for Duchenne muscular dystrophy and C. difficile infection, will be reporting its third quarter financial results for the period ending 31 October 2015 on Thursday, 17 December 2015.

About Summit Therapeutics Summit is a biopharmaceutical company focused on the discovery, development and commercialisation of novel medicines for indications for which there are no existing or only inadequate therapies. Summit is conducting clinical programs focused on the genetic disease DMD and the infectious disease Clostridium difficile infection. Further information is available at www.summitplc.com and Summit can be followed on Twitter (@summitplc).

For more information, please contact:

Summit Glyn Edwards / Richard Pye (UK office)Erik Ostrowski / Michelle Avery (US office)	Tel: +44 (0)1235 443 951   +1 617 225 4455
Cairn Financial Advisers LLP(Nominated Adviser)Liam Murray / Tony Rawlinson	Tel: +44 (0)20 77148 7900
N+1 Singer (Broker)Aubrey Powell / Jen Boorer	Tel: +44 (0)20 7496 3000
Peckwater PR(Financial public relations, UK)Tarquin Edwards	Tel: +44 (0)7879 458 364tarquin.edwards@peckwaterpr.co.uk
MacDougall Biomedical Communications(US media contact)Chris Erdman	Tel: +1 781 235 3060cerdman@macbiocom.com